secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oric Pharmaceuticals, Inc. (ORIC)
CIK:        0001796280
Form:       8-K
Filed at:   2022-12-21T23:59:59+00:00
Accession:  0001193125-22-310169
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ORIC Pharma partners with Pfizer on ORIC-533 Phase 2 combo study; Pfizer invests $25M
--------------------------------------------------------------------------------

- Pfizer to invest $25M for 5,376,344 shares at $4.65/share in registered direct offering.
- ORIC and Pfizer will conduct a Phase 2 study of ORIC-533 combined with elranatamab in multiple myeloma.
- Jeff Settleman, Pfizer Oncology CSO, joins ORIC's Scientific Advisory Board.
- ORIC retains full ownership of ORIC-533; net proceeds extend cash runway into 1H 2025.
- Offering expected to close Dec 23, 2022; no underwriter or placement agent involved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1796280/000119312522310169/0001193125-22-310169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1796280/000119312522310169/d399008d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-310169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer